Literature DB >> 19814964

Ongoing rubella outbreak in Bosnia and Herzegovina, March-July 2009--preliminary report.

A Novo1, J M Huebschen, C P Muller, M Tesanovic, J Bojanic.   

Abstract

Between 24 March and 31 July 2009, 342 clinically diagnosed cases of rubella were notified in five municipalities in Republika Srpska, Bosnia and Herzegovina. Fourteen cases were laboratory-confirmed by positive IgG against rubella virus. Four virus isolates were obtained and identified as genotype 2B strains, with one isolate differing by a single mutation in the region of the E1 gene. This ongoing outbreak revealed gaps in the immunisation programme during the war in BiH (1992-1995) and highlights the need to revise legislation to permit immunisation of children above 14 years of age with measles, mumps, rubella (MMR) vaccine and to introduce supplemental immunisation activities.

Entities:  

Mesh:

Year:  2009        PMID: 19814964     DOI: 10.2807/ese.14.39.19343-en

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  4 in total

1.  Associations between SNPs in candidate immune-relevant genes and rubella antibody levels: a multigenic assessment.

Authors:  V Shane Pankratz; Robert A Vierkant; Megan M O'Byrne; Inna G Ovsyannikova; Gregory A Poland
Journal:  BMC Immunol       Date:  2010-10-05       Impact factor: 3.615

2.  Effects of armed conflict on child health and development: A systematic review.

Authors:  Ayesha Kadir; Sherry Shenoda; Jeffrey Goldhagen
Journal:  PLoS One       Date:  2019-01-16       Impact factor: 3.240

3.  The intergenerational effects of war on the health of children.

Authors:  Delan Devakumar; Marion Birch; David Osrin; Egbert Sondorp; Jonathan C K Wells
Journal:  BMC Med       Date:  2014-04-02       Impact factor: 8.775

4.  Rubella immune status of neonates - a window towards seroprevalence among childbearing women.

Authors:  Iris Pejcic; Milica Rankovic Janevski; Aleksandra Knezevic; Djordje Jevtovic; Maja Stanojevic
Journal:  BMC Public Health       Date:  2016-08-19       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.